WuXi AppTec Co. Ltd. (WuXi), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, today announced that the small molecule active pharmaceutical ingredient (API) and advanced intermediate manufacturing facility located in Jinshan Shanghai, which is part of its subsidiary Shanghai SynTheAll Pharmaceutical Co., Ltd. (STA), recently successfully passed a general GMP and Pre-Approval Inspection from the U.S. Food and Drug Administration with no Form 483s issued. This is the third time that STA's Jinshan facility passed the U.S. FDA inspection.